Here's why Bliss GVS Pharma shares have surged over 45% over the last 10 sessions

Shares of Bliss GVS Pharma Ltd. gained in early trade on Wednesday, June 3, after the company said its facility in Palghar East, Maharashtra is in compliance with the good manufacturing practices (GMP) standards of the World Health Organization (WHO).

The pharma firm, in an exchange filing on Tuesday, June 2, said it received an inspection closure report for the manufacturing unit from the WHO regarding the same.

Recent Major Transaction

On May 23, 2026, Anupam Rasayan India Ltd. approved the acquisition of up 74.2% stake in Bliss GVS Pharma.

Last week, Anupaman Rasayan India's deputy CFO Vishal Thakkar told

CNBC-TV18 that the company sees significant scope to improve Bliss GVS Pharma's capacity utilization and margins over the next two to three years, supported by stronger access to markets such as the US, Europe and India.

Ever since the acquisition announcement, shares of Bliss GVS Pharma have risen over 45%.

The stock has traded with gains in nine out of the last trading sessions before Wednesday's trade.

Share Price Performance

Shares of Bliss GVS Pharma are now trading with gains of 1.7% at ₹441.7 on Wednesday. The stock has now risen 61% in the last one month. With this move, the stock has gained over 170% so far in 2026.

The stock has seen gains in all six months of the calendar year so far. Shares had followed up a 28% advance in April, with a 54% surge in the month of May, majority of which came after the Anupam Rasayan Transaction.

This is the best calendar year return that the stock has had so far since 2015, when the stock had gained 177%. In case the stock surpasses these levels, it will be the best calendar year returns for the stock going all the way back to 2007.

Also Read: Stocks To Buy: After 45% fall from peak, online car portal gets an upgrade; Check target